StockNews.com assumed coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company's stock.
Nymox Pharmaceutical Stock Performance
Shares of NASDAQ NYMX opened at $0.42 on Friday. Nymox Pharmaceutical has a fifty-two week low of $0.19 and a fifty-two week high of $2.10. The company has a market cap of $37.57 million, a PE ratio of -4.15 and a beta of 0.62. The business has a 50-day simple moving average of $0.36 and a two-hundred day simple moving average of $0.38.
Get
Nymox Pharmaceutical alerts:
Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter.
Institutional Trading of Nymox Pharmaceutical
A hedge fund recently bought a new stake in Nymox Pharmaceutical stock. Citigroup Inc. bought a new position in shares of Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 109,079 shares of the biopharmaceutical company's stock, valued at approximately $137,000. Citigroup Inc. owned approximately 0.12% of Nymox Pharmaceutical at the end of the most recent quarter. 0.78% of the stock is currently owned by hedge funds and other institutional investors.
About Nymox Pharmaceutical
(Get Rating)
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
- 2 Biotechs Making Waves With A Single Product in their Pipeline
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com承担了对以下股票的报道尼莫克斯制药(纳斯达克:NYMX-GET Rating)在周日上午发布的一份报告中。该公司对这家生物制药公司的股票发布了卖出评级。
Nymox制药类股表现
上周五,纳斯达克纽约证交所的股价开盘报0.42美元。Nymox Pharmtics的股价为0.19美元,为52周低点,52周高点为2.10美元。该公司市值为3757万美元,市盈率为-4.15,贝塔系数为0.62。该业务的50日简单移动均线切入位在0.36美元,200日简单移动均线切入位在0.38美元。
到达
尼莫克斯制药公司警报:
纽约莫克斯制药公司(纳斯达克代码:NYMX-GET Rating)最近一次发布季度收益报告是在11月14日星期一。这家生物制药公司公布了本季度每股收益(EPS)(0.02美元)。
Nymox制药公司的机构交易
一家对冲基金最近购买了Nymox制药公司的新股。根据花旗集团向美国证券交易委员会提交的最新的Form 13F文件,花旗集团在第一季度购买了纽约医药公司(Nymox Pharmtics Co.)的新股票头寸(代码:NYMX-GET Rating)。该机构投资者买入了这家生物制药公司109,079股股票,价值约13.7万美元。截至最近一个季度末,花旗集团持有Nymox Pharmtics约0.12%的股份。该股目前由对冲基金和其他机构投资者持有0.78%的股份。
Nymox制药公司简介
(获取评级)
Nymox制药公司是一家生物制药公司,在加拿大、美国、欧洲和国际上从事老龄人口药物的研究和开发。它的主要候选药物是Fexapbon Trifltate(NX-1207),它已经完成了治疗良性前列腺增生症的第三阶段临床试验,以及治疗低级别局限性前列腺癌的第二阶段临床试验,以及肝细胞癌的临床前研究。
专题报道
- 免费获取StockNews.com关于NYMOX制药公司(NYMX)的研究报告
- 好时为什么是一只甜蜜的衰退股票
- 亚马逊股票是否会在2023年为投资者提供服务?
- 分析师将货运情绪转回远期
- 各机构预订波音航班
- 两家生物技术公司在其流水线中以单一产品掀起波澜
获得Nymox药学日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Nymox制药公司和相关公司的最新新闻和分析师评级的每日简要摘要。